European Union

European Union

Merck's VAXNEUVANCE Receives Expanded Indication Approval in the European Union for Prevention of Pneumococcal Disease

The European Commission has approved an expanded indication for Merck's (NYSE: MRK) VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) to include active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae) in infants, children, and adolescents from 6 weeks to less